INTRODUCTION {#sec1-1}
============

In the last decades, the number of elderly patients continued to increase dramatically to be 8.5% of the current world\'s population and is expected to reach about 17% by 2050.\[[@ref1]\] In parallel, hypertension (HTN) tends to increase with age affecting more than 75% of people older than 75 years in the United States.\[[@ref2][@ref3]\] Due to the high prevalence of multiple comorbidities, frailty, and poly-pharmacy, the management of HTN in geriatric population is more challenging than in younger patients. Furthermore, older patients were minimally represented in HTN trials, leaving several unanswered clinical questions for physicians who provide care to this age group.

The optimal blood pressure (BP) control should achieve the maximum preventive benefits without causing harms or complications. Yet, this target in the elderly is still controversial. In this article, we review the trials that studied the efficacy and safety of different BP targets in old patients and discuss the guidelines which were released recently from different medical societies.

METHODS {#sec1-2}
=======

Using PubMed, we conducted a literature review to analyze the trials which were published in English in the last 10 years (between 2008 and 2017) which specifically included patients aged 70 years or older. We used in our search the words "hypertension," or "blood pressure" combined with "elderly," "geriatrics," "older than 70 years," "septuagenarians," "octogenarians," "or "nonagenarians." All other studies which do not meet these criteria were excluded. At the end, a manual search of the references of the selected articles was performed to look for any relevant articles that we might have missed.

WHY THE HYPERTENSION MANAGEMENT IN THE ELDERLY IS SPECIAL? {#sec1-3}
==========================================================

For many years, HTN was considered a physiological response of aging related to degeneration of elastic fibers and deposition of calcium and collagen in the arterial walls.\[[@ref4]\] However, various studies have shown that HTN is not a benign finding in elderly patients but can be a strong independent risk factor of morbidity and mortality of cardiovascular diseases.\[[@ref5][@ref6]\] Besides, many clinical trials have proven that appropriate management of HTN reduces the risk for cardiovascular diseases, cerebrovascular diseases, and death.\[[@ref7]\]

That being said, the strict control of BP in geriatric population raises valid concerns of increasing the risk of hypotension, especially in those older than 80 years. Interestingly, it is estimated that more than half of octogenarian and nonagenarian patients are at risk of having masked hypotension which means they may develop hypotension at home even if they have normal BP in the office visit.\[[@ref8]\] This risk was especially reported in those with diabetes, coronary heart disease, or who are on many antihypertensive medications.\[[@ref8]\] Due to frailty, hypotension in the elderly can associate with a higher risk of falls, leading to serious fractures and immobility.\[[@ref9]\] Moreover, several studies have shown that hypotension due to antihypertensive agents can result in frequent incidences of stroke and acute renal failure, besides an increase in all-cause and cardiovascular mortalities.\[[@ref10][@ref11][@ref12]\]

Since both HTN and medication-related hypotension are associated with an increased mortality and poor outcomes, it is widely believed that the relationship between BP and mortality and morbidity in older patients shows a J-curve (or U shape) phenomenon. In other words, BP in geriatric population must be controlled to avoid stroke and cardiovascular diseases but without causing hypotension, falls, and other complications. To define this perfect range of BP, two different questions should be addressed: first, what is the ideal BP goal in the elderly to achieve the maximum benefits of antihypertensive therapy? And second, to which level can we safely control BP without causing harm or increasing mortality?

IS LOWERING BLOOD PRESSURE TARGETS MORE BENEFICIAL IN THE ELDERLY? {#sec1-4}
==================================================================

Although the benefits of BP management are indisputable, it was unclear whether intensive control of BP is superior to moderate control in geriatric population or not. Using our search criteria, we identified five trials which have been specifically conducted in patients older than 70 years to answer this question. [Table 1](#T1){ref-type="table"} summarizes the findings of those studies.

###### 

Review of trials which studied the benefits of different blood pressure targets in patients older than 70 years of age

  Study (year)               The age of included population (years)   The average follow-up (years)   Study design                    Number of patients   Conclusions
  -------------------------- ---------------------------------------- ------------------------------- ------------------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  HYVET (2008)               \>80                                     1.8                             Randomized controlled trial     3845                 Control BP to \<150/80 mmHg decreases fatal stroke, all-cause mortality, any cardiovascular events, and heart failure
  VALISH (2010)              \>70                                     3.07                            Randomized, open-label trial    3260                 No difference was seen between strict (\<140 mmHg) and mild control of BP (140-150 mmHg) in terms of composite cardiovascular diseases
  Wei *et al*., (2013)       \>70                                     4                               Randomized, open-label trial    724                  Achieving BP \<140/90 compared to BP \<150/90 decreased total and cardiovascular mortality and reduced the rate of stroke
  SPRINT (2016)              \>75                                     3.14                            Randomized controlled trial     2636                 Lower rates of cardiovascular events and death were seen with SBP target of \<120 mmHg compared with an SBP target of \<140 mmHg
  Delgado *et al*., (2017)   \>80                                     4.4                             Observational cohort analysis   79,376               The lowest mortality was observed in individuals with SBP of 135-154 mmHg

HYVET: Hypertension in the Very Elderly Trial, VALISH: Valsartan in Elderly Isolated Systolic Hypertension, SPRINT: Systolic Blood Pressure Intervention Trial, SBP: Systolic blood pressure, BP: Blood pressure

The earliest study was the Hypertension in the Very Elderly Trial (HYVET) which randomly assigned individuals older than 80 years with initial SBP \>160 mmHg to either treatment or placebo.\[[@ref13]\] With medications, the reduction in BP to 150/80 mmHg resulted in significant decrease in the incidence of fatal stroke, all-cause mortality, any cardiovascular events, and heart failure. Moreover, after applying per-protocol analyses, the active treatment of the elderly added more benefits such as decreasing the rate of any stroke by 34% and the rate of death from cardiovascular causes by 27%.\[[@ref13]\]

A further lower BP threshold was tested in 2013 by Wei *et al*. who investigated the outcomes in old patients treated to achieve BP \<140/90 mmHg compared to those with BP \<150/90 mmHg.\[[@ref14]\] The authors of this study found that intensive treatment decreased total and cardiovascular mortality by 41.7% and 50.3%, respectively. Furthermore, intensive management reduced the rate of stroke by 42.0% and heart failure death by 62.7%.\[[@ref14]\]

Another important study to determine the optimal target of BP control in the elderly was the Systolic Blood Pressure Intervention Trial (SPRINT). This study enrolled patients older than 75 years with SBP \>160 mmHg to compare the benefit of intensive versus standard BP control in this age group. The authors found that treating SBP target of \<120 mmHg compared with SBP target of \<140 mmHg has reduced the incidence of cardiovascular disease by 33% and total mortality by 32%.\[[@ref15]\]

However, the results of these studies were challenged by the negative results of the Valsartan in Elderly Isolated Systolic Hypertension (VALISH) study which failed to show a difference in the composite of cardiovascular events between patients who were treated to achieve SBP \<140 mmHg and those who had SBP at 140--150 mmHg.\[[@ref16]\] We should notice, however, that the BP difference between the two groups in this study was merely 5.4/1.7 mmHg which was small to definitively determine any effect of these strategies.\[[@ref16]\]

Recently, Delgado *et al*. performed an analysis of the database of more than 79,000 patients who were aged 80 years and older. In this cohort, the lowest mortality was found in individuals with SBP of 135--154 mmHg, suggesting it as an optimal range of BP in the elderly.\[[@ref17]\] Despite the importance of this trial, these findings should be carefully assessed being only observational data and can be affected by many unavoidable confounding factors.

In summary, the available literature tends to support that better BP control is beneficial in patients older than 70 years. The positive outcomes included an improvement in mortality, cardiovascular events, and stroke. These benefits were seen even with minimal BP control such as keeping SBP \<150 mmHg and continued with more intense SBP control of \<120 mmHg.

WHAT IS THE THRESHOLD TO SAFELY CONTROL BLOOD PRESSURE IN THE ELDERLY? {#sec1-5}
======================================================================

The safety of BP control is the other very important component of HTN management in the elderly particularly since several early population-based studies suggested that lowering BP in older patients may associate with worsening mortality.\[[@ref18][@ref19][@ref20][@ref21][@ref22]\]

Although safety was not one of the endpoint outcomes of the HYVET study, the results revealed no difference between the placebo and the active-treatment group regarding the changes in electrolytes and kidney function after 2 years of follow-up. Besides, the reported serious adverse events were comparable in the two groups.\[[@ref13]\]

The VALISH trial found that BP of \<140 mmHg can be safely achieved in healthy patients older than 70 years old.\[[@ref16]\] The rates of adverse events such as renal failure, gastrointestinal symptoms, or respiratory symptoms were similar in the two groups. This was also correct for more serious adverse events which were reported equally regardless of BP control strategy.\[[@ref16]\]

Wei *et al*. showed comparable rates of femoral fractures and vascular dementia in older patients regardless of whether they were treated to achieve BP \<140/90 or BP \<150/90.\[[@ref14]\] Similarly, the risk of fragility fractures was the same for different SBP targets in the cohort study conducted by Delgado *et al*. However, in this study, there was a high mortality in those with SBP \<135 mmHg and more heart failure when SBP was \<125 mmHg.\[[@ref17]\] Yet, interpreting these observational findings is somehow challenging since hypotension can be a direct result of heart failure.

The safety of more intense BP control continues to be debated. For instance, a recent retrospective observational cohort study has found SBP of \<120 mmHg in patients over the age of 70 years associated with mortality, acute kidney injury, and hospital admission. Again, due to the design of this study, it was difficult to say for sure whether the hypotension was the responsible factor or this was due to severe illness which may be the primary reason of mortality, hospitalizations, and poor outcomes.\[[@ref23]\]

On the other hand, the results of SPRINT study advocated the safety of more strict control of BP to \<120 mmHg. In this trial, the overall serious side effects, the number of injurious falls, syncope, and the prevalence of orthostatic hypotension were comparable between the two groups of SBP above and below this threshold. Moreover, there was no difference between the two groups in terms of electrolyte abnormalities, acute kidney injury, or renal failure.\[[@ref15]\] Many controversies, however, have sprung around SPRINT due to difficulties in generalizing these results to the geriatric population as the trial excluded older adults residing in nursing homes, persons with type 2 diabetes and other comorbidities, and those with low standing BP \<110 mm Hg.\[[@ref15]\]

In general, it is fair to say that a good BP control in patients aged 70 years or more seems to be safe and not associated with increased risk of fall, fractures, or kidney failure. Although SPRINT demonstrates, against to the previous beliefs, that lowering SBP to \<120 mmHg is harmless, we should realize that this threshold is evaluated in a selective group of geriatric population. More well-designed studies are needed to evaluate the safety threshold in patients who are very old, have several comorbidities, or taking many medications.

THE TARGET OF BLOOD PRESSURE CONTROL ACCORDING TO THE PUBLISHED GUIDELINES {#sec1-6}
==========================================================================

Due to the complexity of BP management in the elderly, several medical committees have released their specific guidelines on when to initiate pharmacotherapy and the best goal of BP management in elderly patients. Depending on the evolving evidence over the last few years, different targets have been suggested. [Table 2](#T2){ref-type="table"} summarizes the various guidelines and the level of their evidences.

###### 

Review of published guidelines of blood pressure management in geriatric population

  The committee                                                 Year               Age (years)        Threshold to initiate medical therapy   Target of BP control           Class of recommendations   Level of evidence
  ------------------------------------------------------------- ------------------ ------------------ --------------------------------------- ------------------------------ -------------------------- -------------------
  NICE                                                          2011               \>80               BP \>160/100 mmHg                       BP \<150/90 mmHg               N/A                        N/A
  \<80                                                          BP \>140/90 mmHg   BP \<140/90 mmHg   N/A                                     N/A                                                       
  ESH and ESC                                                   2013               \>80               SBP \>160 mmHg                          SBP between 140 and 150 mmHg   Strong                     High
  \<80                                                          SBP \>140 mmHg     SBP \<140 mmHg     Moderate                                Low                                                       
  JNC 8                                                         2014               \>60               BP \>150/90 mmHg                        BP \<150/90 mmHg               Strong                     Moderate to high
  CHEP                                                          2016               \>80               SBP \>160 mmHg                          SBP \<150 mmHg                 N/A                        Low
  75-80                                                         SBP \>130 mmHg     SBP \<120 mmHg     N/A                                     Moderate                                                  
  ACP and AAFP                                                  2017               \>60               SBP \>150 mmHg                          SBP \<150 mmHg                 Strong                     High
  SBP \>140 mmHg for patients with a history of stroke or TIA   SBP \<140          Weak               Moderate                                                                                          
  SBP \>140 mmHg for patients at high cardiac risk              \<140              Weak               Low                                                                                               
  Many societies including AHA/ACC, ASH, and AGS                2017               \>65               BP \>130/80                             BP \<130/80                    Strong                     High

AAFP: American Academy of Family Physicians, ACC: American College of Cardiology, ACP: American College of Physicians, AGS: American Geriatric Society, AHA: American Heart Association, BP: Blood pressure, CHEP: Canadian Hypertension Education Program, ESC: European Society of Cardiology, ESH: European Society of Hypertension, JNC 8: Eighth Joint National Committee, N/A: Not available, NICE: National Institute of Health and Care Excellence, SBP: Systolic blood pressure, ASH: American Society of Hypertension, TIA: Transient ischemic attack

In 2011, the National Institute of Health and Care Excellence recommended a higher target for patients older than 80 years compared to the general population.\[[@ref24]\] Likewise, the European Society of Hypertension and European Society of Cardiology suggested to lower SBP to \<150 mmHg in elderly individuals with SBP ≥160 mmHg. However, elderly patients who are younger than 80 years and fit and tolerant to treatment should be managed to maintain BP.\[[@ref25]\]

In 2014, the Eighth Joint National Committee updated their BP guidelines and recommended starting medical management in patients aged 60 years or older when their BP is higher than 150/90 mmHg and to keep it all the time less than this threshold.\[[@ref26]\]

A new Canadian Hypertension Education Program guideline agreed on higher targets of patients older than 80 years. However, they considered patients aged between 75 and 80 years at a high risk and recommended to initiate treatment if SBP is \>130 mmHg aiming to a SBP target of \<120 mmHg.\[[@ref27]\]

While the guidelines of American College of Physicians and the American Academy of Family Physicians suggested to treat HTN when SBP is more than 150 mmHg in elderly patients with low risk factors, more intense target was recommended if the patient has a history of stroke or cardiovascular events.\[[@ref28]\]

The most recent recommendations were released by several American societies including the American Heart Association/American College of Cardiology, American Geriatrics Society, and American Society of Hypertension. These guidelines are important being the first scientific paper to recommend the same HTN treatment goals in persons who are older and younger than 65 years.\[[@ref29]\] Instead of age, the new guidelines determined target BP based on a combination of absolute cardiovascular disease risk and BP level. Since the majority of old patients have a history of cardiovascular disease or a high atherosclerotic cardiovascular disease, BP of 130/80 mmHg was considered a reasonable treatment goal in geriatric population.\[[@ref29]\]

In a review, we can notice a tendency in the recent guidelines to lower BP targets for older patients, especially in those who are considered at a higher cardiovascular risk. Yet, these guidelines recommended to use clinical judgment, patient preference, and team-based approach to assess the risk/benefit of management, especially in those with dementia, advanced heart failure, and nursing home residents.\[[@ref29][@ref30]\]

CONCLUSION {#sec1-7}
==========

HTN is a very common and challenging disease in geriatric population. Although the benefits of BP control in the elderly are well documented, the optimal BP target in this group is still controversial. The most recent guidelines suggested a treatment goal of 130/80 mmHg in patients older than 65 years. However, many factors need to be considered to reach this goal, and clinical judgment and team-based approach is recommended. Additional studies are required to evaluate patients who are very old or those with other comorbidities who used to be either excluded or underrepresented in previous studies.
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